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Abstract 
 Retinoblastoma is a cancer that develops within the retina of the eye. Although it 
may be found in adults, retinoblastoma cases seen globally are mostly in young children. 
Therefore, it is also categorized among the childhood cancers, along with leukemia, bone 
cancer, and neuroblastoma.1,2 If retinoblastoma is treated at its initial stages, the cancer is 
curable. However, if left untreated, this malignant tumor spreads out from the eye and 
may only be treated with enucleation. Enucleation is the last resort to treating the cancer 
because it requires the complete removal of the eye. In order to avoid enucleation, 
various chemotherapy treatments have been developed, which utilize an array of drugs 
such as etoposide. Dunkel et al presented a study that showed successful management of 
retinoblastoma with chemotherapy.3 Among the drugs prescribed during chemotherapy, 
etoposide was one of them. As an inhibitor of topoisomerase, etoposide directly affects 
the growth of retinoblastomas at the core, the DNA, and affects the cell cycle of the 
retinoblastoma cells. The result is a reduction in tumor growth; the cells do not properly 
divide and cannot contribute to the growth of the tumor.  
 For this thesis, a hypothetical treatment was created to study the efficacy of 
etoposide with a higher dosage on tumor reduction. The dosage was increased from 75 
mg/m2 to 90 mg/m2 for a single cycle length of 7 to 15 days. Simultaneously, the dosages 
prescribed before the start of the clinical trial will remain unchanged for the duration of 
each cycle. Utilizing the higher dosage, it is hypothesized that the higher dosage will 
cause a reduction in tumor size among the patients. The higher dosage will be delivered 
via a slow-releasing oral capsule. It is hypothesized that the slow-releasing capsule will 
allow children to take a higher dosage of the drug for a longer cycle and, therefore, result 
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in a significant reduction in tumor size. Although the clinical trial may not be carried out 
under the circumstances at the time of this thesis, it is predicted that a large majority of 
the patients will present a significant reduction in tumor size.  
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Introduction 
Purpose 
 The purpose of this honors thesis is to utilize the information provided through a 
review of retinoblastoma and its various treatments available to propose a hypothetical 
clinical trial that may potentially be carried out. The hypothetical clinical trial will focus 
on etoposide, which is one of the main chemotherapeutic drugs used in treating 
retinoblastoma. Etoposide, prescribed with other chemotherapeutic drugs such as 
carboplatin and thiotepa, has been found to be effective in the management and reduction 
of tumor size.4,5,6 Etoposide, as well as other commonly used chemotherapeutic drugs, is 
restricted due to toxic effects on the normal cells and tissues of the body. Young children 
form the bulk of patients that receive etoposide in a mixture, or cocktail, of other 
chemotherapeutic drugs. Therefore, the proposed clinical trial will present a higher 
dosage, which will be taken orally in a time-released oral capsule. By using an extended 
release oral dosage, it is hypothesized that the higher dosage will present better results in 
terms of the management and reduction of the tumor size.  
 
Background 
 Retinoblastoma is a malignant tumor of the retina. It is a hereditary disease that 
accounts for 4% of all childhood cancers and is most commonly found in children of ages 
0-4.7,8 Retinoblastoma appears in the retina as a white mass with many calcifications, or 
accumulation of calcium deposits. The mass may develop in various directions. 
Retinoblastoma is classified as either intraocular, the tumor is present within the eye, or 
extraocular, the tumor has spread to areas around the eye. An intraocular retinoblastoma 
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may be bilateral, present in both eyes, or unilateral, present in only one eye. An 
extraocular retinoblastoma may be an orbital retinoblastoma or metastic retinoblastoma. 
Orbital retinoblastomas are tumors that have only spread to the eye socket. Metastic 
retinoblastomas are tumors that have spread to distant parts of the body such as the brain.  
 
 
 
 
 
 
Figure 1. Anatomy of the Human Eye – cross-sectional view9 
 The retina converts the images that enter through the eye’s lens to electrical 
signals, which are sent to the brain through the optic nerve. The retina is light-sensitive 
and contains photoreceptors, cones and rods across its surface.10 As seen in Figure 1, The 
retina is positioned posterior to the lens of the eye and receives a large supply of oxygen 
due to the large number of blood vessels present, which gives it its red color.4 The retina 
is relatively visible when a light is shown through the pupil as it is dilated. A color 
change in the retina may be one of the first signs of a disease. In the case of 
retinoblastomas, when the retina is observed through the dilated pupil, leucocoria, a white 
tumor, is seen, which marks the beginning stages of the disease. 
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Figure 2. Retinoblastoma Samples: (a) Retinoblastoma invasion of the choroid but 
not the optic nerve. (b) Retinoblastoma invasion of the optic nerve11 
 
The retinoblastoma cells that become extraocular invade other areas of the eye 
including the choroid, as seen in Figure 2.6 In a sample, the tumor cells are distinctly 
darker than the cells of the healthy tissue. As the retinoblastoma cells continue to invade 
areas around the retina, the healthy tissues are rapidly affected. Eventually, if left 
untreated, the retinoblastoma cells will reach the optic nerve. In Figure 2b, the 
retinoblastoma cells have proliferated significantly and most of the optic nerve has been 
affected; there is little healthy tissue present. 
Although fatal if left untreated, retinoblastoma has developed into a curable disease since 
its first identification in the 1500s. In 1597, Peter Pawius of Amsterdam was the first person to 
provide a description of a tumor of what is now retinoblastoma in a three-year-old. In 1809, 
James Warthrop, a Scottish surgeon, of Edinburg defined retinoblastoma as a unique 
clinicopathologic entity. The term “retinoblastoma” did not appear until the 1920s, when 
Hermann Von Helmholtz, a German physicist and physician, proposed the name. Helmholtz 
believed that the tumor arose from embryonic retinal cells. The American Opthalmological 
Society adopted the term in 1926. The exact date at which retinoblastoma became curable is not 
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known, but treatments were present since the 1930s. The pioneer work on possible treatments for 
retinoblastoma was done by Dr. Algernon Reese and Dr. Hayes Martin.12,13 Enucleation had been 
the primary option to treat retinoblastoma, but Dr. Reese and Dr. Martion were able to treat and 
save patients using radiation therapy. 
 Retinoblastoma was originally thought to be a fungating mass that resulted in the 
destruction of the internal construction of the eye. A fungating mass, or wound, forms when the 
growing cancer breaks through the epithelial tissue, or skin.14 However, the extensive molecular 
research based on the work of Kyritsis et al. concluded retinoblastoma was a cancer that results 
from the overproduction of immature retinal cells. There is also large evidence that genetics is a 
factor in the presence of retinoblastoma.15 Chromosomal abnormalities as well as spontaneous 
mutation have become key players in identifying and explaining retinoblastoma.   
Retinoblastoma cells have shown a distinct rosette-like arrangement (Figure 3). 
Predominant retinoblastoma cells are described as “a round cell with basophilic nucleus of 
variable size and relatively little cytoplasm.”16 The nuclei present pleiomorphic changes as well 
as mitotic figures. As seen in Figure 3, more clearly differentiated areas present the distinct 
arrangement seen. The rosette-like arrangement has been determined to be a distinct, or 
pathognomonic, characteristic of retinoblastoma. A study performed by Ts’o, Fine, and 
Zimmerman revealed the rosettes, formed by cuboidal tumor cells, originated from 
photoreceptors and the comparable lining of the lumen of the rosette to the outer membrane of the 
retina.17  
 
 
 
 
 
 
 
 
 
 
Figure 3. Retinoblastoma cells that present a rosette-like arrangement.18 
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Figure 4: Retinoblastoma cells that form long cell processes.4 
 
Tumor Growth and Diagnosis 
Retinoblastoma tumor growth may be endophytic or exophytic. Endophytic 
growth represents growth into the vitreous, interior of the eye, which contains a 
gelatinous mass, and emerges from the inner layers of the retina. On the other hand, 
exophytic growth emerges from the outer layers of the retina and represents growth under 
the retina toward the choroid. Retinoblastoma tumor growth may also be a mix of both 
endophytic and exophytic growth. Diffuse infiltrating tumor growth represents a grayish 
plaque present on the retinal surface. Retinoblastoma may also be identified as 
intraocular or extraocular. Intraocular retinoblastoma describes tumor growth that is still 
contained within the eye. Extraocular retinoblastoma describes tumor growth that has 
spread from the interior of the eye, such as into the optic nerve.  
Extraocular retinoblastoma is a risk factor for metastatic growth due to the 
invasion into the optic nerve, which creates a more accessible path into the central 
nervous system.9 Extraocular retinoblastoma is localized to the optic nerve beyond the 
margin of resection or to the soft tissues surrounding the eye.19 The location of tumor 
development is a vital factor in determining the amount of visual loss that is experienced. 
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In one study, using a visual field analysis, various degrees of visual loss were 
examined.20 The patients were placed in one of four groups: no residual defect, absolute 
scotoma, arcuate scotoma, and pseudo-visual field defect. Scotoma refers to partial loss 
of vision; it may also refer to the presence of a blind spot in normal visual field. Arcuate 
represents the shape of the loss of visual field in which the loss of vision begins at a blind 
spot and curves around to the nasal field of vision. The relationship between the location 
of the tumor to visual loss is that if the tumor is present only at the blind spot, where the 
retina is attached to the other nerve, vision is not completely gone. However, once the 
tumor begins to move out from the blind spot, vision loss becomes more prominent and 
may eventually result in complete vision loss.  
Aside from the retina, the optic nerve and the central nervous system are affected 
by retinoblastoma. Optic nerve involvement is mostly seen in retinoblastomas due to its 
direct connection to the retina. The central nervous system is affected when the disease 
has reached a metastatic level. The tumor is classified using the Reese-Ellsworth 
classification, which contains five groups, Group I to Group V, based on tumor size and 
location.21,22 Group I designates tumors as very favorable for maintenance of sight and 
are relatively small. Group I includes solitary tumors that are smaller than 4 disc 
diameters (DD), which is based on the size of the optic disc, and multiple tumors that are 
no larger than 4 DD. The solitary tumors are at or behind the equator. The equator of the 
eye is the plane that is equidistant to the anterior and posterior ends of the eye. Group II 
designates tumors as favorable for maintenance of sight and include solitary and multiple 
tumors with a size that ranges from 4 DD to 10 DD. The solitary tumors are at or behind 
the equator. The multiple tumors are all behind the equator. Group III designates tumors 
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as possible for maintenance of sight. This group includes solitary tumors that are larger 
than 10 DD and any lesions anterior to the equator. Group IV designates tumors as 
unfavorable for maintenance of sight. This group includes multiple tumors that may be 
larger than 10 DD and any lesions extending anteriorly to the ora serrata. The ora serrata 
is the jagged junction between the retina and ciliary body.23 Group V designates tumors 
as very unfavorable for maintenance of sight. This group includes significantly large 
tumors that reach a size of one-half of the retina and vitreous seeding. Seeding in 
retinoblastoma tumors is seen when small pieces of the tumor have broken off and are 
floating around the vitreous.  
The Internal Classification of Retinoblastoma (ICRB) is also used to categorize 
the various tumors. Unlike the Reese-Ellsworth classification, ICRB categorizes tumors 
according to the extent of tumor seeding within the subretinal space and vitreous cavity. 
ICRB contains also five categories, A to E, and utilizes tumor size, location and absence 
of subretinal and vitreous seeds. As a patient moves up the classification, such as B to E, 
it will become more difficult to control the growth of the tumor and preserve as much 
useful vision as possible. Patients present in Group A display small intraretinal tumors 
that are 3 mm or smaller in greatest dimension and are present away from the foveola and 
disc, farther than 3 mm from foveola and 1.5 mm from optic disc. Group B presents all 
tumors that are discrete and are confined to the retina; these tumors are distinct from 
those present in Group A. Group C presents discrete tumor(s) with minimal subretinal or 
vitreous seeding. Subretinal and vitreous seeding refer to tumors that have broken apart 
and are present in the subretinal or vitreous portion of the eye. Patients classified into 
Group D present tumor(s) that may be massive or diffuse and the disease presents 
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significant vitreous or subtretinal seeding. Group E indicates one or more signs of poor 
prognosis such as tumor touching the lens of the eye, opaque media from hemorrhage, 
and diffuse infiltrating retinoblastoma.3 Patients classified into Group E have limited 
treatments available due to the low probability of preserving any vision in the eye.   
 
 
 
 
Figure 5. Slit-lamp photograph of multiple white nodular tumors present in the 
inferior anterior chamber.24 
 
 
 
 
 
Figure 6. Right: Unilateral Retinoblastoma – tumor seeding in the iris. Left: 
Vitreous seeding4 
 
In diagnosing retinoblastoma, the most common sign of the presence of 
retinoblastoma is leucocoria.3 Leucocoria is the white tumor that is reflected in the 
presence of light and blocks the view of the retina. The white tumor is life-threatening 
and is the first sign of the tumor growth, which is still contained in the interior of the eye. 
The presence of leucocoria in children may be observed if the pupils naturally dilate in 
dim light as a beam of light is shone on the eyes. Figures 5 and 6 display the presence of 
leucocoria, which may be confined to one area, Figure 5, or spread out, Figure 6.4,15 If the 
treatment is begun within 3 to 6 months of discovering leucocoria, retinoblastoma is 
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curable; the tumor is still intraocular. The effectiveness of treatment for retinoblastoma 
begins to decrease as treatment is delayed after the first sign of leucocoria is discovered. 
If the cancer is not responsive to chemotherapy, enucleation is the only option available 
to treat retinoblastoma.  
 
Genetics 
Genetics plays a large role in the diagnosis and treatment of retinoblastoma. 
Retinoblastoma is a hereditary disease when it is transmitted as an autosomal dominant 
trait. The autosomal dominant inheritance is present in retinoblastoma that contains a 
mutation within the germline, the reproductive cells in the body.25 However, there have 
been cases in which retinoblastoma is the result of a de novo mutation. The 
retinoblastoma-1 gene has been localized to chromosome 13q14, or more specifically 
13q14.2.26,27 According to Online Mendelian Inheritance in Man (OMIM), 
retinoblastoma is not the only phenotype that is expressed as a result of microdeletions of 
DNA in this region. Microdeletions are chromosomal deletions that span across several 
genes but are too small to be detected under the microscope using conventional 
cytogenetic methods.28 Cytogenetic analysis is the basic element of diagnosing genetic 
disorders caused by chromosomal abnormalities.29 The basic method of cytogenetic 
analysis is fluorescence in situ hybridization (FISH). To detect microdeletions, genetic 
tests such as microarrays and whole exome sequencing are commonly used. Microarrays 
and whole exome sequencing allow a more in depth analysis of the various 
microdeletions that may be present on each chromosome. By running a patient’s 
chromsomes through a robotic machine, which is able to run hundreds to thousands of 
gene sequences placed on a single microscope slide, results obtained immediately present 
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any microdeletions or abnormalities that may have been documented to cause various 
diseases.  
Aside from retinoblastoma, microdeletions on this chromosome result in somatic 
osteosarcoma, somatic bladder cancer, and somatic small cell cancer of the lung.10 The 
retinoblastoma gene (RB1) was also the first tumor suppressor to be cloned. The function 
of the RB1 gene contains the characteristics of a regulatory element of the cell cycle. The 
function of the gene is controlled by a phosphorylation/dephosphorylation mechanism in 
various stages of cell proliferation and differentiation.30 
The retinoblastoma protein, Rb, functions as an active transcriptional repressor 
while it is attached to a promoter through binding with E2F.31 E2F is also known as 
Transcription Factor E2F, Retinoblastoma-Binding Protein 3 (RBP3), and 
Retinoblastoma-Associated Protein 1 (RBAP1). Rb may interact with transactivating 
domains that surround transcription factors on the protein. By surrounding these factors, 
the interaction is blocked with a basal transcription complex. Rb can also recruit histone 
deacetylase while it is bound to E2F. Histone deacetylation is the removal of negatively 
charged acetyl groups to histones.32 Histone acetylation stabilizes the nucleosomes and 
prevents transcription. The nucleosomes are induced by histone acetylation to assemble. 
Rb is bound to E2F during the recruitment of histone deacetylase and blocks the access of 
transcription factors to the promoters. With the formation of Rb-E2F complexes, E2F 
sites operate as transcriptional silencers.  
When a defective gene copy of chromosome 13q14 undergoes somatic mutation, 
the result is the loss of the normal remaining copy of the gene.  Experiments have shown 
that retinoblastoma tumor formation results in the loss of chromosome during mitotic 
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divisions of predisposed cells.33 According to research done by Zhang et al., 
retinoblastoma showed the lowest mutation rate reported in human cancer to date.34 The 
ploidy, a number or set of chromosomes within a cell, of retinoblastoma cells were stable 
in vitro and in vivo despite many instances in which retinoblastoma cells presented 
mitotic defects. These defects could lead to errors in chromosome segregation.  
 Heritable retinoblastoma requires two mutations, which includes a mutation in the 
germline and another in the developing retina. Germline mutation is present in 90%-95% 
of patients with bilateral retinoblastoma.35 In heritable retinoblastoma, an Rb gene 
mutation is present in most of the cells of the body, if not all. The Rb gene mutation 
results in the inactivation of the both alleles of the Rb gene, which categorizes 
retinoblastoma as an autosomal recessive cancer.4 Autosomal recessive retinoblastoma is 
found in patients that do not contain a mutation in the germline.20 Non-heritable 
retinoblastoma also requires two mutations but both mutations occur in the developing 
retina. Due to the presence of the mutation in non-germline cells, patients with autosomal 
recessive retinoblastoma usually do not pass on the Rb gene mutations. However, genetic 
testing is highly advised to verify the location of the Rb gene mutation.  
 Those with a de novo mutation cannot be traced back to a family member for 
he/she contains a spontaneous mutation that occurred during fertilization. For patients 
with retinoblastoma family history, a pedigree may be created from genetic testing to 
identify the possibility of having a child with retinoblastoma. Genetic counseling plays an 
important role in keeping families educated on the disease as well as providing solutions 
to obtain treatment as soon as possible.  
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Treatments 
As the understanding of retinoblastoma developed, various treatments emerged. 
The treatments include enucleation, external beam radiation therapy, focal therapy, laser 
photocoagulation, thermotherapy, and system chemotherapy. Enucleation was introduced 
by Warthrop after his observation in 1809. Warthrop identified this treatment as a life-
saving measure for patients with retinoblastoma. Enucleation, by definition, involved the 
complete removal of the eye containing the tumor. This treatment was performed on 
patients in whom extraocular extension had yet to occur. However, during the time of 
Warthrop, enucleation was avoided due to high mortality rate after the procedure. The 
development of anesthesia, as well as the presence of antibiotics, resulted in fewer 
traumas after enucleation and, therefore, reduced the mortality rate. Von Graefe, a 
pioneer of German opthamology, identified that retinoblastoma often grew into and down 
the optic nerve into the brain. Graefe advised that a long stump of the optic nerve be 
removed in the enucleation. This remains the standard practice today.36 Today, 
enucleation is used when there is no presumption that any useful vision can be preserved. 
Enucleation involves the removal of the eye and may also include the removal of the 
optic nerve if it has been invaded. For highly lethal retinoblastomas and Group E tumors, 
enucleation is the only solution. 
Chemotherapy refers to the use of a drug or chemical to treat an illness. Many 
times chemotherapy is automatically thought to refer only to cancer treatment.  One type 
of chemotherapy is systemic chemotherapy. Systemic chemotherapy uses anticancer 
drugs in its treatment, which travels to cells throughout the body through the 
bloodstream.37 Another type of chemotherapy is intra-arterial chemotherapy. Intra-aterial 
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chemotherapy is a newer treatment that includes intravascular cannulation of the 
ophthalmic artery.38 A tube is inserted in the ophthalmic artery to allow direct delivery of 
chemotherapy to the eye and areas surrounding the eye.  
Stem cell rescue is an approach in treating metatastic retinoblastomas. Stem cell 
rescue is a technique that harvests the stem cells of the patient receiving chemotherapy 
that uses lethal doses of drugs.39 During the length of the chemotherapy treatment, the 
tissue of the bone marrow is heavily destroyed. Therefore, the harvested stem cells are 
placed back into the patient after high-dose chemotherapy and used to help the bone 
marrow recover from the treatment and make healthy cells. After healthy cells have been 
made and replaced in the patient, another cycle of chemotherapy can be performed after 
another round of harvesting stem cells, which will be replanted after the treatment. Stem 
cell rescue is used to allow patients to undergo many chemotherapy treatments that 
require lethal doses of chemotherapeutic drugs. 
High-dose chemotherapy, also known as bone marrow transplant, is another 
treatment used to treat retinoblastoma. In an experiment by B. Kremens, et. al, high-dose 
chemotherapy was performed with thiotepa, an alkylating agent, etoposide, and 
carboplatin.40 The dosage for etoposide was 40 mg/kg and the dosage for carboplatin was 
1.5 g/m2. The transplantation involves peripheral hematopoietic stem cells and is an 
attempt to increase the survival rate of children with metatastic retinoblastomas. For the 
children used in the experiment, thiotepa and carboplatin were not prescribed; the drugs 
prescribed were BCNU, cyclophosphamide, and etoposide. The dosage used on the child 
was 1.6 g/m2. Thiotepa, carboplatin, BCNU, and cyclophosphamide are all alkylating 
agents. Alkylating agents work by directly damaging DNA and, therefore, directly 
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blocking the cancer cells from reproducing. Alkylating agents target various stages of the 
cell phase and used to treat not only retinoblastoma but other cancers as well, such as 
leukemia and ovarian cancer.41  Alkylating agents are found to have long-term effects on 
the body, such as damage to bone marrow, due to its direct effect on DNA. 
Cyclophosphamide belongs to a class of alkylating agents called nitrogen mustards. 
Nitrogen mustards are a derivative of nitrogen gas and were discovered to have an effect 
on bone marrow and white blood cells. BCNU, or carmustine, belongs to the class of 
alkylating agents called nitrosoureas. Nitrosoureas are found to be the most active among 
the anticancer drugs “both qualitatively and quantitatively.”42 Nitrosoureas interfere with 
the enzymes that are needed for DNA repair and are able to pass the blood-brain barrier, 
which represents its involvement in the treatment of retinoblastomas. Thiotepa belongs to 
the class of alkylating agents called ethylenimines. Similar to the other classes of 
alkylating agents, it interferes with DNA processes and is found to be highly reactive 
when protonated. Carboplatin belongs to the class of anticancer drugs called platinum 
drugs, which are sometimes grouped with alkylating agents. The mechanism of action of 
platinum drugs are similar to that of alkylating agents, but are found to have a lower 
chance of causing leukemia later in life. Etoposide belongs in a different group of 
anticancer drugs called topoisomerase inhibitors, which interfere with the enzyme 
topoisomerase.  
Aside from chemotherapy, which utilizes drugs such as etoposide, there are other 
treatments available for patients with retinoblastoma. The different types of treatment 
include external beam radiation therapy, focal therapy, and ophthalmic artery 
chemosurgery. Each treatment tackles various groups of tumor growth and is 
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continuously studied and advancing as alternative treatments. Enucleation is a very 
common treatment as well, but it is the extreme choice when all other treatments do not 
show any signs of improvement. Enucleation is also performed if the patient wishes to 
remove the tumor entirely, which may include the optic nerve in certain cases.  
External beam radiation therapy has been the preferred vision-sparing treatment 
for many years. It is used on progressive or persistent retinoblastomas after chemotherapy 
and focal treatment. It is also used on retinoblastoma cases in which vitreous or subretinal 
seeding has occurred. Abramson et al. interprets their data to suggest that external beam 
radiotherapy may be the only treatment that will potentially cure and spare the patients 
from significant long-term visual complications.20 
Focal therapy refers to a group of treatments that are applied directly to the eye 
and are used on small tumors that are not located at the center of vision or the optic 
nerve. For tumors that are determined to be too large for focal therapy, chemotherapy is 
the first method of treatment in order to shrink the tumor size. There are three main types 
of focal therapy: cryotherapy, laser therapy, and brachytherapy. Cryotherapy is a type of 
focal therapy in which an instrument is used to repeatedly freeze the tumor and thaw it at 
temperatures as low as -60˚C to -80˚C.43 The tumor cells are targeted and killed through 
the process of thawing. The ice crystals penetrate the tumor cell’s membranes. 
Cryotherapy is used primarily on small peripheral retinoblastoma tumors. Laser therapy 
utilizes heat to physically destroy the tumor cells and is used on small tumors as well as 
residual and reoccurring tumors of retinoblastoma. Brachytherapy, also known as 
radioactive plaque, consists of a small disc that is surgically placed directly over the 
tumor. The disc contains a small amount of radioactive material that is delivered at small 
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doses directly to the tumor. The disc is present for two to five days before it is surgically 
removed. Brachytherapy is not used on tumors near the optic nerve and/or the center of 
vision. However, brachytherapy is used when the retinoblastoma has not responded to 
crytotherapy and laser therapy.  
Ophthalmic artery chemosurgery is intra-arterial chemotherapy modified.3 It is 
delivered through the external carotid artery when the ophthalmic artery cannulation is 
impossible. David H. Abramson modifies the chemotherapy treatment by noting that the 
largest proportion of the blood flow usually goes to the supratrochlear artery and not 
directly to the eye.16 The aim of the experiment is to reduce the dose of melphalan, an 
alkylating agent. The results reveal that the lower does had no hematologic toxicity. 
Although it was originally used as chemical warfare, its effect on bone marrow and white 
blood cells was discovered.44  Also, after treating eyes that were to be enucleated, the 
results show that 58% of eyes were saved. Ophthalmic artery chemosurgery makes it 
possible to save the most severe of retinoblastomas that would have been enucleated.  
 
Etoposide 
Etoposide is a derivative of podophyllotoxin, one of the compounds found in 
podophyllin (Figure 7).45 The drug was introduced in 1971 and has become one of the 
first-line drugs for treating various cancers. It treats cancers such as small cell lung 
cancer, acute nonlymphocytic leukemia, and lymphomas. The effects of etoposide, along 
with a large variety of other podophyllotoxin derivations, are mediated by topoisomerase 
II and interact with DNA. Topoisomerases are “enzymes that are involved in changing 
the supercoiled state of DNA.”46 Topoisomerase II belongs to the second class of 
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topoisomerases that cut the ends of both strands of DNA, pass parts of DNA between the 
cut ends, and reseal the DNA. Etoposide specifically prompts the breakage of the double-
stranded DNA by forming the cleavable complex.47 The cleavable complex is a complex 
formed between DNA and topoisomerase II. The cleavable complex creates a toxic effect 
due to the conversion of an essential enzyme, topoisomerase II, into a cellular toxin. 
Topoisomerase II is an essential enzyme which alters DNA topology and is required to 
resolve “knots and tangles” in the genetic material. The knots and tangles are produced 
by normal cellular processes, which include DNA replication and recombination.48 
Despite the common use of etoposide in cancer treatment, it is found to have moderate 
potency, metabolic inactivation, toxic effects, poor water solubility, and may result in the 
development of restistance. According to the BC Cancer Manual, the distribution of the 
drug depends on a patient’s weight. On average, the prescribed dosage is 32% of a 
patient’s body weight, which ranges from 7 to 17 L/m2.49  
 
 
 
 
 
Figure 7. Etoposide Structure50 
Within the five-ring system of podophyllotoxin, the rings labeled A and E in 
Figure 8 indicate the pharmacophores. A pharmacophore is portion of the compound that 
is responsible for biological activity. Ring A contains a methylenedioxy ring that is 
crucial for optimal antitumoral activity. The low potency is due to the hydroxy groups on 
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carbon 3 and 5 on ring E. However, despite the low potency, the hydroxyl groups play a 
role in the stabilization of topoisomerase II DNA intermediates.18 By modifying the 
groups attached to the fourth carbon in ring C, such as bulky groups, the anticancer and 
topoisomerase activities are amplified. As can be seen in etoposide, unlike the hydroxyl 
group (-OH) attached to carbon 4 in podophyllotoxin, etoposide contains a rather bulky 
group at carbon 4 of ring C. Any changes to ring B will lead to a loss of activity.  
 
 
 
 
 
 
 
Figure 8. Structure of Podophyllotoxin43 
According to an experiment performed by Debra L. Friedman, et al., etoposide, 
prescribed with carboplatin and vincristine, presented positive results for those with 
tumors classified as Reese-Ellsworth groups 1-3. By prescribing these drugs during 
systemic chemotherapy, treatments became available to treat retinoblastoma and 
eliminated enucleation as only option of managing the tumor.51 Etoposide was found to 
be effective in treating retinoblastomas and avoiding as the only treatment to control 
tumor growth. Etoposide has also been used in the management of metastatic tumor 
growth after enucleation.52 Due to the fact that etoposide has shown many positive results 
in treating retinoblastoma, a clinical trial can be performed to focus on the effects of 
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etoposide. By emphasizing the dosage of etoposide, its effect on treating retinoblastoma 
can be more prevalent and, therefore, lead to an array of treatments that may present 
positive outcomes.  
 
Hypothesis 
Etoposide is commonly taken to treat retinoblastoma. It is specifically chosen for 
this hypothetical clinical trial to treat retinoblastoma because, aside from it being a 
commonly prescribed drug, it belongs to a class of drugs that directly affect the core of 
tumor growth. Tumors are the result of irregular cell growth, which is directly affected by 
DNA replication. Etoposide works at the core of DNA replication by damaging the DNA 
to prevent any further cells from reproducing. This clinical trial focuses on reducing 
tumor growth and, therefore, etoposide is the best drug to prescribe. By targeting the 
effects of increasing its dosage, it may provide the treatment needed to reduce tumor 
growth. Due to the fact that other drugs are simultaneously taken, the dosage varies 
depending on the chemotherapy and the group of tumor growth. In a potential clinical 
trial, all patients participating will receive etoposide as well as all other drugs prescribed. 
However, the patients that are placed in the experimental group will receive an elevated 
dosage of etoposide while the dosages of all other drugs will remain the same. The 
patients not in the experimental group will receive the dosage before it was elevated. By 
increasing only the dosage of etoposide, it can be assumed that any reduction of tumor 
size that occurs will be due to the higher etoposide dosage. The dosage of all other drugs 
will not be reduced and remain consistent before, during, and after the trial to focus on 
the effect of etoposide. If the experimental group presents reduced tumor size, it can be 
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concluded that it is due to the higher etoposide dosage.  In other words, if the patients 
who do not receive the higher dosage do not show signs of tumor reduction, the 
relationship between the higher dosage of etoposide and tumor reduction becomes 
clearer. The clinical trial will focus solely on the effect of etoposide as the main drug 
with the highest efficacy in the treatment of retinoblastoma tumor growth. As the tumor 
growth categorization goes down, such as from B to D, the effect of dosage increase may 
not have substantial effects. However, retinoblastomas of group C to E will be included 
for this clinical trial to provide random and normal sampling.  
The hypothesis for this clinical trial is that when the dosage of etoposide increases 
from an average of 75 mg/m2/day to 90 mg/m2/day and taken for single cycle length of 7- 
15 days, there will be signs of tumor reduction among the patients. According to the 
British Columbia Cancer Agency, BC Cancer Agency, the usual dose of etoposide given 
orally is 50 mg – 100 mg PO (orally) once daily for 3-10 days.31 The 3-10 days refer to a 
single cycle length, which is a single period of chemotherapy given. In a study performed 
Dunkel et al, the etoposide dosage was 250 mg/m2/day for 3 days.3 This dosage is higher 
than what is proposed for this hypothetical clinical trial, but given in a shorter period. 
Therefore, the dosage that has not been elevated will be 75 mg/m2/day but given for a 
longer period.  The dosage was also determined based on the draft guidance of etoposide 
provided by the U.S. Food and Drug Administration.53 The draft guidance recommends 
an oral dosage that is estimated to be twice the dosage given intravenously. It is 
hypothesized that the dosage for IV injections is approximately 37 mg/m2/day to 38 
mg/m2/day.  
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The higher dosage of etoposide has been chosen as the center of this hypothetical 
clinical trial because in high-dose chemotherapy, etoposide has shown positive results in 
treating the tumor by reducing tumor size.40 By increasing the number of days in a cycle 
from 3-20 days to 7-15 days, it is hypothesized that the higher dosage will present a 
reduction in tumor size among the patients 
What is unique to this hypothetical trial is evaluating the effect of a higher dosage 
of etoposide. Like all other chemotherapeutic drugs, to advance in the number of 
treatments available, different dosages of etoposide may be tested. However, in other 
clinical trials, etoposide is present in a cocktail and the dosages of all drugs vary but are 
elevated somewhat equally.54,55,56 By elevating only etoposide within the cocktail and 
maintaining the concentrations of the other drugs, the effects of etoposide on tumor 
reduction may be observed and analyzed. 
Although intravenous (IV) injections are the standard procedure in the distribution 
of etoposide and other chemotherapy drugs, for this clinical trial, the focus will be on the 
oral distribution, or capsule, of etoposide given each cycle length. There are many FDA-
approved dosages for intravenous distribution of etoposide57 On the other hand, there is 
only one FDA-approved dosage for the capsule distribution, which is 50 mg distributed 
by the drug company Mylan.58 Many clinical trials also focus on various dosages 
distributed through IV. Therefore, utilizing the clinical trials that discuss the oral 
distribution of etoposide, a hypothetical clinical trial will be created in search of a dosage 
that may potentially be FDA-approved and distributed. Despite the focus of oral 
distribution for this trial, it is important to know that many patients receive etoposide 
intravenously only, orally only, or intravenously and orally. Patients may receive IV 
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injections of etoposide during hospitalized stays, but during this trial, the patients will 
only receive etoposide orally. All other drugs will continue to be distributed as normal, 
which may be IV injections. 
A slow-releasing capsule will be used to distribute the higher dosage of etoposide, 
which may result in lowering toxicity and alleviate toxic shock.  Toxic shock occurs 
when the body reacts to healthy cells that are destroyed by drugs used in chemotherapy. 
This occurs because drugs prescribed during chemotherapy are poisonous. Therefore, the 
drugs are not used for prolonged periods, but in high dosages for short periods of time. 
For this trial, the slow-releasing capsule will allow a higher dosage to be prescribed for a 
longer single cycle of chemotherapy. 
The body weight of the patients selected for this trial will be highly focused due 
to its large contribution in the process of determining a safe dosage of etoposide. 
Although the dosage is not significantly increased, it is assumed it is high enough to show 
results among the younger age group. The higher dosage is assumed to be safe for the 
clinical trial, which will be determined through blood work and supervision throughout 
the clinical trial.   
For this trial, etoposide will be given in a slow-releasing capsule. The effect of a 
slow release will potentially reduce the level of toxicity present at the body at one 
moment. By controlling the rate at which etoposide will be released into the body, the 
level of toxicity may also be controlled. It is hypothesized that a higher dosage of 
etoposide could cause the body to react through toxic shock. To mediate, or counteract to 
a certain extent, the slow-releasing capsule will provide the parameters to prevent a 
severe response to the higher dosage of etoposide. The slow-releasing capsule is also 
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used for this clinical trial to study its efficacy of a higher dosage of etoposide for 
children. It is hypothesized that the slow-releasing capsule will allow allowing a higher 
dosage of etoposide to be prescribed for a prolonged period of time, 7-15 days.The body 
will not go into toxic shock as the dosage of etoposide is released in this hypothetical 
treatment. There are many drugs currently on the market that utilizes slow-releasing 
capsules such as Tylenol and Advil. 
James R. Lawter and Michael G. Lanzilotii patented the composition of the 
microencapsulation for drugs that are slow-releasing in October 1990. The company that 
originally distributed the microencapsulation was the American Cyanamid Company. The 
composition of the capsules included the volatile silicone fluids that were used in the 
hardening of the capsule. These silicone fluids included octamethylcyclotetrasiloxane and 
decamethylcyclopentasiloxane; both molecules are volatile, can be easily evaporated at 
room temperature.59 Many slow-releasing capsules are now made with a cellulose 
derivative polymer called hydroxypropylmethylcellulose; it is also called methocel.60 As 
a cellulose derivative polymer, hydroxypropylmethylcellulose forms a consistent drug 
diffusion through the gel that forms when it is hydrated. The release of the drug is 
controlled by the diffusion of the drug across the gel and through the dissolution of the 
soluble drug into the water, which penetrates into the drug core after it dissolves the 
capsule.  
In an experiment by A. Solano, et. al, the effects of a sustained release of 
etoposide in a poly(ε-caprolactone), PCL, implants were studied.61 Polycaprolactone, a 
non-toxic, biodegradable polymer, is used commonly in controlled drug delivery due to 
its high permeability to several drugs. It also has the possibility of a long, sustained drug 
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release rate and can be fully excreted from the body. Using the Melt Method, etoposide 
was thoroughly dispersed into the PCL that had melted. The results of this experiment 
showed promising results with approximately 12% of etoposide being released during the 
first 15 days in analysis performed on the implant, in vitro. The first phase presented a 
small burst of fast release. However, results showed a gradual decrease in release rate 
with approximately 66% of etoposide released in the second phase. Results performed in 
vivo also presented similar results with approximately 19% of the drug being released 
from the implant during the period between the 6th and 25th day of the trial. 
Using the results from Solano’s experiment, it can be predicted that the higher 
etoposide dosage will be released slowly, which will allow the body to take on the higher 
dosage. If the PCL implants were to be utilized for the hypothetical trial, the higher 
dosage will have approximately 12%-19% of etoposide released from the implants. There 
also would not be safety concerns regarding the long-term effects of using a slow-
releasing capsule due to PCL’s ability to be fully excreted from the body. Although the 
body may retain levels of etoposide, the effects of the drug will be not be elevated due to 
the use of a slow-releasing capsule.  
 
Materials and Methods 
 In a potential clinical trial, a group of 240 children varying from the ages of 3 
months to 10 years will be studied. Hypothetically, 240 children will be chosen to 
accommodate for any patients that will have to drop out in the middle of the trial. It is 
highly unlikely that the results will be obtained from all 240 children. The reasons behind 
why some of the children will be removed from the trial will be discussed in the results 
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section. 120 children will be placed in the experimental group and receive the capsule 
with the elevated dosage of etoposide. The other 120 children will be placed in the 
control group and receive the dosage before it was increased, which is 75 mg/m2/day. The 
control group will be used to directly observe the effect of the increased dosage of 
etoposide. For both the experimental and control group, all patients will continue to 
receive the dosages of all other drugs prescribed prior to the clinical trial. The children 
will be recruited from hospitals such as Mount Sinai, New York Presbyterian, and North 
Shore. All participants will be chosen randomly among the children that have been 
diagnosed with retinoblastoma at any of these hospitals. In order to provide the most 
accurate information, ophthalmologists will perform a variety of thorough examinations, 
which includes a comprehensive dilated eye exam62 and magnetic resonance imaging 
(MRI), on each patient. Neurologists will also study the MRI photos taken to truly 
understand the extent of the growth of tumor for each patient. The identification of the 
tumor growths of each patient will vary from Group A to Group E, with Group E being 
the most severe. Any patients with tumors that have reached the stage at which 
enucleation is the only treatment available have been dismissed.  
The comprehensive dilated eye exam will be performed to allow an examination 
of the interior of the eye seen through the pupil. By widening the pupil, the 
ophthalmologists will be able to visualize the extent of the tumor growth to a certain 
extent. If the tumor growth has reached Group C in its classification, it should be visible 
during this test. The tumor may be immediately visible on the lower region of the iris or 
may be visible when the ophthalmologists examine the interior region of the eye, 
including the vitreous. The MRI will be done to obtain a more extensive image of the 
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tumor growth within the eye. As seen in Figure 9, the eye that contains the tumor is 
substantially larger than the other. However, the size of the eye on the images will not be 
the defining characteristic for the presence of a tumor. The MRI images of the patients 
will be compared to those of normal subjects, subjects that do not present any 
chromosomal abnormalities or presence of tumor growth in the eye. With the results of 
the MRI image comparisons, the eligibility of all 300 patients will be verified in order to 
continue the clinical trial.  
 
 
 
 
 
 
Figure 9. MRI of extraocular extension of retinoblastoma3 
Once the patients have been verified, a full physical examination will be 
performed. Along with the physical examination, blood work will be completed to record 
the blood pressure, iron levels, and cholesterol levels. Blood work will also be performed 
specifically to confirm that the patients are not taking any drugs that will affect the 
clinical trials by interacting with the pharmacophore of etoposide. Special care will be 
taken to ensure the blood work and physical examination is precisely and accurately done 
to ensure the right dosage is being given to each patient. This is to ensure no child 
receives a dosage that may be lethal to his/her body.  
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During the duration of the clinical trial, which will extend from approximately 5 
to 10 years, regular blood work as well as renal and hepatic, liver, function will be 
performed every 2 weeks for the duration of the trial. These tests will be performed to 
closely monitor white blood cells as well as red blood cells to assess the presence of 
haematological toxicity.63 Haematological toxicity tests check for neutropenia, anemia, 
and thrombocytopenia. Neutropenia is an abnormally low count of white blood cells, 
anemia is an inadequate amount of red blood cells to carry oxygen throughout the body, 
and thrombocytopenia is a low blood platelet count.64,65,66 Platelets stop bleeding through 
clumping, which block the blood vessels. The blood work will be performed regularly to 
monitor the levels of etoposide in the body and its relation to haematological toxicity. If 
levels of etoposide are detected to be too high, precautions will be taken to ensure the 
levels do not become lethal. Precautions will also be taken with any detection of high 
levels in regards to haematological toxicity, which may be a sudden fluctuation of white 
blood cells, of red blood cells, and/or of blood platelet count. If etoposide levels are 
detected to be lethal and signs of haematological toxicity are present, the patients will be 
immediately released from the trial. Dilated eye exams and MRIs will also be taken every 
6 months for all patients.  
The level of toxicity will be evaluated using the Common Toxicity Criteria, 
version 2.0, in the case of an adverse event. 67 An adverse event describes any symptom 
or disease that is a momentary result of the use of the drug during a treatment or 
procedure that may or may not be considered affiliated with the treatment or procedure. 
Toxicity levels will be checked at two points during the duration of the trail. The 
Common Toxicity Criteria is used to categorize the effects of various drugs administered 
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as part of cancer treatments. There are 6 grades: grade 1 represents no adverse event or 
within normal limits, grade 1 represents a mild adverse event, grade 2 represents a 
moderate adverse event, grade 3 represents a severe and undesirable adverse event, grade 
4 represents a life-threatening or disabling adverse event, and grade 5 represents a death 
related to adverse event. The first checkpoint will be in 5 years, the halfway point of the 
trial. For any patients that are presenting anything greater than grade 2 will receive a 
lower dosage. Measures will be taken to ensure all patients stay within grades 0 to 2, 
preferably grade 0.  
  
Expected Results 
Among the 240 patients that are to participate in this clinical trial, it is assumed 
approximately 90% will be able to complete the full trial. It is possible that 24 patients, 
will have to drop out of the trial due to different reasons. The reasons may include 
moderate to severe side effects to etoposide, such as fainting, hair loss, eye pain, 
difficulty breathing or swallowing, and seizures.68 Patients that present any signs of 
tumor growth will be removed immediately to ensure the proper treatment and 
medications are provided. If the patients have tumors within Group D or E, enucleation 
will be performed to prevent any further spread of the tumor.  
Side effects are expected regardless of the dosage given. The following side 
effects are commonly seen in patients taking etoposide through oral prescriptions: fever, 
cough, chills and temporary hair loss.69 Hair is expected to grow back once the etoposide 
treatments are completed. In the experiment performed by B. Kremens, et. al, patients 
presented side effects such as diarrhea and severe mucositis, which is commonly seen in 
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cancer patients undergoing treatments.40 Mucositis occurs when the rapidly dividing 
epithelial cells that line the gastro-intestinal tract break down and become vulnerable to 
ulcerations and infection. The patients received analgesics, or painkillers, as well as 
antibiotics to mediate the effects. Other side effects present were nausea and vomiting. 
Similar to the experiment, if any side effects are present in the patients, appropriate 
treatments will be given to alleviate them. In an extreme case, if the patients are 
experiencing severe side effects that are hindering the effects of etoposide, they will be 
removed and treated immediately.  
Along with the side effects stated above, the etoposide levels will be thoroughly 
checked in internal organs, such as the liver and kidneys. If etoposide levels are found to 
be low, the patients will be left to complete the trial. If etoposide levels are found to be 
moderate to severely high, the patients will be removed immediately due to the 
possibility of liver or kidney damage. The patients will be given the appropriate 
treatments to lower etoposide levels and treat any possible signs of liver and kidney 
damage. 
From the remaining 216 patients that will complete the trial, a success rate will be 
determined at approximately 85% of patients with reduced tumors. For the children who 
were admitted at the first site of leucocoria, depending on the type of treatment used with 
etoposide, the intraocular tumor will be significantly reduced at an increased dosage.   
 
Discussion 
 The results of this clinical trial may vary depending on the type of patients that 
participate. To find accurate results of the effect of increasing the dosage of etoposide, an 
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actual clinical trial will have to be performed. Among the 90% who complete the trial, it 
is hypothesized that most of the patients who received the elevated dosage presented 
reduced tumors. Etoposide is an FDA(U.S. Food and Drug Administration)-approved 
drug.70  
 Etoposide contains properties that target the source of the tumor growth, the 
cells. By interrupting the supercoiling of DNA and the cell cycle, the retinoblastoma cells 
will not divide as quickly, which will lead to control of tumor growth. A higher dosage 
may result in more control, but, without proper guidance and instructions, the higher 
etoposide dosage may result in high toxicity levels in the body as well as resistance. It is 
assumed that the etoposide was given properly throughout the entire clinical trial, which 
includes all proper medications were taken with etoposide, the etoposide was taken at all 
proper times, and the etoposide was not mixed with anything that may hinder the effects 
of the drug or immensely enhance them.  
 Resistance is an important factor during this clinical trial. Some of the patients 
that do not show reduction in tumor size may be because of resistance to etoposide. One 
of the characteristics of etoposide includes possibility of resistance. The resistance may 
appear earlier in the clinical trial and may possibly appear after the trial. If the resistance 
appears after the trial, it must be taken into account. The follow-ups after the clinical trial 
are designed to keep track of the reduction of tumor size without the higher dosage of 
etoposide. After observing the patients after the trial, the effects of the higher dosage may 
be prevalent because the tumor will respond to the change in medication dosages. The 
key results that are obtained will be from the follow-ups as well as the end of the clinical 
trial.  
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